High-value, specialized chemicals for niche applications, such as coatings, adhesives, and catalysts.
chemXplore tracks 460 projects in specialties, of which 112 are active.
63 new construction, 40 expansion, 4 revamp / retrofit, and 1 conversion / repurposing.
23 of the active projects carry no start-up date yet.
Owners and developers: BASF SE (11), Evonik Industries AG (5), Arkema (4), Asahi Kasei Corporation (3), Vulcan Energy (3), Abu Dhabi National Oil Company Group (2)
Investors: Arkema (3), European Investment Bank (3), Evonik Industries AG (3), ADEME (2), BASF SE (2), Business Finland (2)
Contractors, licensors, and offtakers are recorded on 50 of these 112 projects For subscribers
Targeting: Hydrogen (5), Lithium hydroxide (4), Lithium iron phosphate (4), Carbon dioxide (3), Graphene (3), Lithium bis(fluorosulfonyl)imide (3)
Seven-country Deco sale yields about $1bn net; EV/FY25 EBITDA multiple 21x; closing mid‑2027 (Indonesia late‑2026).
Adherent culture plate with high oxygen permeability, enhanced surface treatment, low autofluorescence and low drug adsorption to improve organoid culture and screening.
Targets +10% recurring EPS CAGR to 2030, recurring ROCE >11%, €40bn+ capital allocation with ~€24bn industrial investments and 33% CO2 cut by 2035.
On-site solar installation will produce ~3,400 MWh/year (~10% of site demand), cut about 1,152 t CO2e annually and was developed with Convergent Energy and Power.
Adhesive Technologies expands into specialty coatings after closing the Stahl deal; Stahl adds leather, performance and packaging coatings, €725m sales and ~1,800 employees.
High-volume, CE-compliant production cell for small automotive connectors delivering 57,600 parts/hr with digital assistance for process stability and high availability.
€10m to triple footprint and modernize the Oullins-Pierre-Bénite battery R&D hub, increasing digitalization and pilot-scale replication of manufacturers' processes.
Report covers PAC growth, GAC commissioning then pause, higher 2025 emissions and energy use, water reductions, land reclamation, safety record and a 2026 baseline for PAC production.
VOYAGER real-world data show Vabysmo improves vision and reduces retinal thickness across wet AMD, DME and RVO, with rapid anatomical drying and no new safety signals.
Combination achieved up to 23.3% weight loss (54.1 lbs) and 2.9% A1C reduction versus 14.8% (34.4 lbs) and 2.4% with tirzepatide; Phase 3 to start Q4 2026.
By country, the most active first. active / all projects
The 8 with the most active projects, of 37 countries.
